Lupin’s subsidiary, MedQuimica acquires rights to nine brands from Bausch Health
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System-related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease
Lupin’s subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc, Lupin notified in a statement.
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System-related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease, the statement added.
- Advertisement -
thanks a lot and keep up the good work.